{"title":"Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy.","authors":"Sho Miyamoto, Takayuki Kanaseki, Yoshihiko Hirohashi, Tomohide Tsukahara, Yasuhiro Kikuchi, Noriyuki Sato, Toshihiko Torigoe","doi":"10.2177/jsci.40.40","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer-stem cells (or cancer-stem like cells, CSC) play an indispensable role in tumor initiation or tumor development in vivo. However, CSCs are resistant to conventional therapies including chemo/radiotherapy and a certain molecularly-targeted therapy, thereby are responsible for tumor relapse or metastasis in clinical settings. In this review, we focus on cytotoxic T-cell mediated immune responses against CSCs and discuss a challenge of targeting CSCs as well as the development of CSC-based cancer immunotherapy, which is an emerging and promising strategy toward a complete cure of quite a few types of cancers.</p>","PeriodicalId":79359,"journal":{"name":"Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology","volume":"40 1","pages":"40-47"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2177/jsci.40.40","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2177/jsci.40.40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Cancer-stem cells (or cancer-stem like cells, CSC) play an indispensable role in tumor initiation or tumor development in vivo. However, CSCs are resistant to conventional therapies including chemo/radiotherapy and a certain molecularly-targeted therapy, thereby are responsible for tumor relapse or metastasis in clinical settings. In this review, we focus on cytotoxic T-cell mediated immune responses against CSCs and discuss a challenge of targeting CSCs as well as the development of CSC-based cancer immunotherapy, which is an emerging and promising strategy toward a complete cure of quite a few types of cancers.